Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications. - Wikidata - wikimedia - TriplyDB

Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications.

Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications.

http://www.wikidata.org/entity/Q33979879

about

Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer Differential expression and tumor necrosis factor-mediated regulation of TNFRSF11b/osteoprotegerin production by human melanomas.Role of denosumab in prostate cancer.Does increased local bone resorption secondary to breast and prostate cancer result in increased cartilage degradation?A genetic polymorphism of the osteoprotegerin gene is associated with an increased risk of advanced prostate cancer.Selection and characterization of a novel agonistic human recombinant anti-TRAIL-R2 minibody with anti-leukemic activity.Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases.The assessment of fracture risk.USP15 targets ALK3/BMPR1A for deubiquitylation to enhance bone morphogenetic protein signalling.Evolving role of bone biomarkers in castration-resistant prostate cancer.Elevated alkaline phosphatase velocity strongly predicts overall survival and the risk of bone metastases in castrate-resistant prostate cancer Change in markers of bone metabolism with chemotherapy for advanced prostate cancer: interleukin-6 response is a potential early indicator of response to therapy.An update on the use of gonadotropin-releasing hormone antagonists in prostate cancer.Evaluation of degarelix in the management of prostate cancer.High bone sialoprotein (BSP) expression correlates with increased tumor grade and predicts a poorer prognosis of high-grade glioma patients.Meta-analysis of genome-wide association studies identifies two loci associated with circulating osteoprotegerin levels Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer Recent advances in the use of serological bone formation markers to monitor callus development and fracture healing Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions.Biochemical markers of bone turnover and clinical outcomes in men with prostate cancer Molecular signaling pathways mediating osteoclastogenesis induced by prostate cancer cells.Value of Procollagen Type I Aminoterminal Propeptide in Women with Breast Cancer with regard to Metastases.High Uric Acid (UA) Negatively Affects Serum Tartrate-Resistant Acid Phosphatase 5b (TRACP 5b) Immunoassay.Osteoblasts in prostate cancer metastasis to bone.Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer.Overcoming drug resistance and treating advanced prostate cancer Association of 12 serum biochemical markers of angiogenesis, tumour invasion and bone turnover with bone metastases from breast cancer: a crossectional and longitudinal evaluation RANK/OPG ratio of expression in primary clear-cell renal cell carcinoma is associated with bone metastasis and prognosis in patients treated with anti-VEGFR-TKIs RANK/RANK-L/OPG in patients with bone metastases treated with anticancer agents and zoledronic acid: a prospective study.Targeting the receptor activator of nuclear factor-kappaB (RANK) ligand in prostate cancer bone metastases.Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer Overexpression of bone sialoprotein leads to an uncoupling of bone formation and bone resorption in mice.Serum N-Terminal Propeptide of Collagen Type I is Associated with the Number of Bone Metastases in Breast and Prostate Cancer and Correlates to Other Bone Related Markers.A list of candidate cancer biomarkers for targeted proteomics.Molecular mechanisms of metastasis in prostate cancer.Osteoblasts stimulate the osteogenic and metastatic progression of castration-resistant prostate cancer in a novel model for in vitro and in vivo studies.Collagenous and non-collagenous biochemical markers of bone metastases from prostate cancer.Rib metastases from a non-tonsillar squamous cell carcinoma in a dog.Human urine proteomics: building a list of human urine cancer biomarkers.Androgen deprivation therapy: past, present and future.

P2860

Q27024775-0AA94B5A-BF05-4806-A1A8-1F7EAA6E5CFE Q30412235-291AA7CE-B359-44E1-9F38-EEBCBCC1E577 Q30455154-65316C85-5E53-4E83-BBE1-B6058A94A35E Q33347582-CE1EB6BC-A053-45F7-9E76-2A615D2C6B8C Q33358300-66FC0A44-32C6-40FC-A4EE-CD4DFF3F928D Q33421148-CF58C02E-A47F-45C4-821E-51232626ABDC Q33441667-B02865FC-9BC8-43EF-95A1-3E369A15B4D4 Q33685092-5362C04F-13BF-41DA-8235-A912B96A2E3A Q33703833-F88A8CCE-723E-4F81-95A4-8A493631063B Q34023877-7076006C-7C7D-40E8-AC1D-172B15EBF1E4 Q34032678-045EBFC1-CAE5-4A97-802A-A4FDEAD6E87A Q34207923-5ED614F2-B9D4-4F04-9506-8A1CFEF4E7C8 Q34214898-F682E0F7-FB90-419F-A32D-9FA8459D2652 Q34417797-F5F21D96-6C99-48D4-823E-9A993DFABADB Q34465050-6A001B4F-2D25-4F79-B17E-B55CB6B52B6E Q34555532-C0CF2D20-CDF2-4683-9CAA-4AA9ACB4C8BA Q34655823-CC9D08C7-3657-46C1-85D5-14E04A077B2F Q34759492-41A1243B-84FD-4DB0-8ADB-D65FE90ABE0B Q34960867-A278BB49-6245-4BA0-A148-AA48373BCFD8 Q35022212-3836151D-54B3-437D-ADB6-3DDBD9DAE04F Q35076418-A367D111-84FD-4C9D-A4F7-1FFDF86B7B4B Q35550827-68A02C2A-4884-44C4-B155-E92C657B98D2 Q35901693-14EB1944-8323-472C-8F72-A92FA52F7E2D Q35998759-535609EA-A599-4235-8155-B097DDA7E84B Q36243296-A58E4770-63D7-46EA-B911-E966C2F514BF Q36328812-AC8F8637-DA21-43E3-B28E-1B6A0BCA8BB4 Q36612227-A222E8B9-8ED9-41B2-8897-AEE8BCF96606 Q36750660-6F8A4633-6097-44BE-9619-8664975ABAC7 Q37007044-9FFB9E6D-7D58-4231-8415-18ECA61DEBFF Q37028352-8DAE4933-30F8-4D57-A30B-18ED93AD54AF Q37198970-6EDD4E80-D8AE-44CE-AC7B-8149A538C373 Q37200578-9FE37945-9889-4BE9-BA31-5A735A456B15 Q37218904-B77ADD89-1462-46C5-985A-4C806B0864B3 Q37277962-FCA78C68-F810-437C-B3B9-F4814267D336 Q37339692-C50A6B12-7849-4FB3-A55D-8393C6B62F8D Q37558837-9F5130EA-5CE9-43B3-ACAA-C9C0A693950D Q37803537-5A0310AA-0B65-4AB3-BDB2-063E6146E53C Q37835863-267CAC9A-87F3-4705-887E-D2F7FCEC6ABA Q37890422-3560D8C5-7F59-4E02-B97F-D6B7C9654E0F Q38016530-163D0B22-F947-4954-AF22-67F11E8FFEF3

P2860

Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications.

http://www.wikidata.org/entity/Q33979879

description

2004 nî lūn-bûn

@nan

2004 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

Comparison of 10 serum bone tu ...... c and prognostic implications.

@ast

Comparison of 10 serum bone tu ...... c and prognostic implications.

@en

type

label

Comparison of 10 serum bone tu ...... c and prognostic implications.

@ast

Comparison of 10 serum bone tu ...... c and prognostic implications.

@en

prefLabel

Comparison of 10 serum bone tu ...... c and prognostic implications.

@ast

Comparison of 10 serum bone tu ...... c and prognostic implications.

@en

P1433

Q33979879-DF4ACD51-11AA-4180-B9F9-408956D23AA9

P1476

Q33979879-06B900DA-21AB-4C98-896C-1BA75414B998

P2093

Q33979879-0D95F6E0-822F-4285-BDFA-4EF11A9C4752

Q33979879-158F82FA-64A4-45EE-8EAE-5548E4992B28

Q33979879-21636586-0246-44BE-8244-FAC956D1417D

Q33979879-2F4AC814-BD7A-4501-BC6A-5DCC66EE9EC5

Q33979879-3D2067A3-463C-4DA1-9BF4-A73F211A7AAC

Q33979879-651A2766-035B-4B23-BCBE-4D5D1B940A91

Q33979879-D189C887-C5FD-4089-95BB-40F265028A93

P2860

Q33979879-12C177B5-3D66-4647-BFC3-26D633808759

Q33979879-146BC286-65E2-479A-9584-D9EE0194FA95

Q33979879-237656C6-01F2-4475-9B0D-8589E12C3891

Q33979879-312262B4-444C-47DF-95E9-A6E3B2E8EA17

Q33979879-462D8FC0-79B6-46CA-874D-5425AB3C157A

Q33979879-4E561A9E-B8A6-453D-B43E-F3AF91F970C5

Q33979879-51F0A1F3-20E0-48FA-970E-B67C2A0F74BB

Q33979879-609A1C8E-4992-4C3F-91F2-C014F6D89D2C

Q33979879-61E703CF-69E3-48BE-8EBD-CADD496F4ECF

Q33979879-67438858-02F5-41D8-B265-A1BA870FCF8D

P304

Q33979879-31406C75-FA1D-427F-A6ED-471B4268DA1E

P31

Q33979879-3877CC71-3839-4C89-9131-DC0A6551C00C

P356

Q33979879-9DAEAE1C-861B-49A9-89FD-289600AD1698

P433

Q33979879-3237682B-7ADD-4755-BD74-25FE77BFE0DD

P478

Q33979879-CF55A6B3-2D1A-4784-9BFA-AA9128340F9F

P50

Q33979879-CC5D2501-CF80-4838-95DE-8B2049492BAD

P577

Q33979879-FAC68F76-4332-411D-BB10-87FF95A69417

P5875

Q33979879-FEC77AE9-C268-44E3-B769-D65A0B795DA7

P698

Q33979879-51D1E239-8AF4-4E2D-8647-76706C5386D5

P356

P1433

International Journal of Cancer

P1476

Comparison of 10 serum bone tu ...... ic and prognostic implications

@en

P2093

Axel Semjonow

http://www.w3.org/2001/XMLSchema#string

Carsten Stephan

http://www.w3.org/2001/XMLSchema#string

Dietmar Schnorr

http://www.w3.org/2001/XMLSchema#string

Katharina Von Hösslin

http://www.w3.org/2001/XMLSchema#string

Michael Lein

http://www.w3.org/2001/XMLSchema#string

Pranav Sinha

http://www.w3.org/2001/XMLSchema#string

Stefan A Loening

http://www.w3.org/2001/XMLSchema#string

P2860

Biochemical markers for the detection of bone metastasis in patients with prostate cancer: diagnostic efficacy and the effect of hormonal therapy.

The serum level of the amino-terminal propeptide of type I procollagen is a sensitive marker for prostate cancer metastasis to bone.

Preanalytical variability of biochemical markers of bone turnover.

Bone markers in the management of patients with skeletal metastases.

Pathophysiology of bone metastases from prostate cancer and the role of bisphosphonates in treatment.

Combined modality treatment for prostate cancer: role of chemotherapy.

Markers of bone turnover for the management of patients with bone metastases from prostate cancer

Biochemical markers of bone metabolism: an overview.

Osteoprotegerin and rank ligand expression in prostate cancer.

Biological variability in assessing the clinical value of biochemical markers of bone turnover.

P304

783-791

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/IJC.20314

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

111

http://www.w3.org/2001/XMLSchema#string

P50

P577

2004-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8456377

http://www.w3.org/2001/XMLSchema#string

P698

15252851

http://www.w3.org/2001/XMLSchema#string